Exploring the interplay between glaucoma and DED
Glaucoma therapy-related ocular surface disease is common, requiring careful management and treatment options consideration.
Jeremy Holyer and Dr Jay Meyer9 min read
Advertisement
Glaucoma therapy-related ocular surface disease is common, requiring careful management and treatment options consideration.
Topical ivermectin 1.0% cream in the treatment of ocular demodicosisMartin Smith et al.Cont Lens Anterior Eye. 2024 Feb;47(1):102099 Review: This retrospective, single-centre study aimed to assess t
When it comes to researching in dry eye, everyone knows I’m the first to tell prospective researchers that ‘the sky’s the limit’. Well, it turns out this might be somewhat of an underestimation! Thank
Auckland's Dr Sid Ogra reviews the latest oculoplastics research.
Eye Surgery Associates’ mid-winter dinner symposium was packed full of eyecare pearls for attending optometrists.
Rohto Mentholatum is the new Australasian distributor for Melcare’s Optimel manuka eye drops for dry eye, which will be distributed in New Zealand and Australia, together with Rohto’s Dry Aid lubrican
Participants in a trial using castor oil treatment for blepharitis were enthusiastic but solutions lie in the long game.
A cutting-edge innovation in topical drops has been described as a breakthrough for sufferers of eye diseases and in ophthalmic drug delivery.
Demodex species form part of our natural microflora but in certain conditions can overpopulate, causing recurrent and persistent blepharitis and meibomian gland dysfunction (MGD). Since Soolantra 1% (ivermectin) cream has been successfully used off-label overseas for several years in the treatment o
Attracting significant interest in the CCLS 2024 exhibition hall, Ophthalmopro’s Eye-Light IPL device complete with low-level light therapy (LLLT) mask enables eyecare practitioners to combine intense pulsed light (IPL) treatments with LLLT to treat dry eye and many other ophthalmic conditions.
LINKS: https://nzoptics.co.nz/live-articles/an-eye-on-understanding-our-lifestyle-choices/
Biopharmaceutical company Telios Pharma has revealed positive topline results from its phase 2 study of TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with dry eye disease (DED).